Temple University

Carlos A Barrero

Salim Merali

Wayne Everett Childers

George C Morton

Steven G Kelsen

Oscar Mauricio Perez Leal

Camilo Moncada

Oscar M Perez-Leal

Mario Cesar Rico

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.

Compositions and methods for treatment of insulin resistance

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders. 

The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease ('COPD') but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.

Treatment of chronic obstructive pulmonary disease (COPD)

Compositions include nucleic acid sequences encoding the C-terminal fragment of fragment (Seg3) of Nuclear factor-erythroid 2 related factor 2 (Nrf2). These compositions provide a target for identification of novel therapeutics having the ability to modulate the translation of Nrf2. Methods of treating subjects are also provided.

Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2

Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD.

Growing community of inventors

Philadelphia, PA, United States of America

Carlos A Barrero